Soleno Therapeutics

SLNO56

High Growth

$51.84arrow_drop_down4.17%-$2.25

High Growth

SLNO56

$51.84

arrow_drop_down4.17%-$2.25

High Growth

Performance History

Key Stats
Open	$54.08
Prev. Close	$54.08
EPS	-2.79
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	54.08	54.08
52 Week Range	21.30	60.14

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.79

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Soleno Therapeutics (SLNO)

Soleno Therapeutics Inc (SLNO) is a healthcare company focused on the development and commercialization of novel therapeutics for rare diseases. The company’s primary focus is on the treatment of Prader-Willi Syndrome (PWS), a genetic disorder characterized by hyperphagia, or insatiable appetite leading to obesity, as well as cognitive and behavioral problems. Soleno’s lead product candidate, DCCR (diazoxide choline controlled-release), is a proprietary once-daily oral tablet that is designed to address the underlying causes of PWS. The company is currently conducting a Phase III clinical trial of DCCR in patients with PWS.

Soleno Therapeutics Inc (SLNO) was founded in 1999 and is headquartered in Redwood City, California. The company’s mission is to improve the lives of patients with rare diseases by developing innovative therapies that target the underlying causes of these conditions. Soleno’s approach is based on a deep understanding of the science behind the diseases it targets, as well as strong partnerships with leading researchers and healthcare professionals. The company is committed to delivering safe and effective therapies that can make a meaningful difference in the lives of patients and their families.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Anish Bhatnagar M.D.
Headquarters: Redwood City
Employees: 25
Exchange: NASDAQ

Keep an eye on Soleno Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Soleno Therapeutics 's (SLNO) price per share?

The current price per share for Soleno Therapeutics (SLNO) is $51.84. The stock has seen a price change of -$2.26 recently, indicating a -4.18% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Soleno Therapeutics (SLNO)?

For Soleno Therapeutics (SLNO), the 52-week high is $60.14, which is 16.02% from the current price. The 52-week low is $21.3, the current price is 143.38% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Soleno Therapeutics (SLNO) a growth stock?

Soleno Therapeutics (SLNO) has shown an average price growth of -4.94% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Soleno Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Soleno Therapeutics (SLNO) stock price performance year to date (YTD)?

As of the latest data, Soleno Therapeutics (SLNO) has a year-to-date price change of 36.6%. Over the past month, the stock has experienced a price change of -3.75%. Over the last three months, the change has been 6.06%. Over the past six months, the figure is 19.17%. Looking at a longer horizon, the five-year price change stands at 122.97%.

help

Is Soleno Therapeutics (SLNO) a profitable company?

Soleno Therapeutics (SLNO) has a net income of -$38.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$41.38M. Furthermore, the EBITDA is -$136.5M.

help

What is the market capitalization of Soleno Therapeutics (SLNO)?

Soleno Therapeutics (SLNO) has a market capitalization of $2.25B. The average daily trading volume is 52.17, indicating the stock's liquidity and investor engagement.

News

Soleno Therapeutics enters agreement to sell $150 million in stock By Investing.com - Investing.com Canada

SOLENO THERAPEUTICS

INSIDER TRADING

STOCK SALE

RESTRICTED STOCK UNITS

Jul 3, 2024

Soleno therapeutics exec sells over $90k in stock By Investing.com - Investing.com

Soleno therapeutics executive sells over $90k in stock By Investing.com - Investing.com

HEALTH

MANAGEMENT STATEMENTS

Jun 28, 2024

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

CHANGES IN COMPANY'S OWN SHARES

Jun 24, 2024

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CALENDAR OF EVENTS

PRODUCT / SERVICES ANNOUNCEMENT

May 22, 2024

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024